MS Drug Pulled from Market Worldwide

MS Drug Pulled from Market Worldwide

A multiple sclerosis (MS) drug is being pulled from the market worldwide after reports of brain inflammation and severe liver damage. Due to safety concerns, Biogen and AbbVie announced that they will be voluntarily withdrawing the drug Zinbryta (daclizumab), an biologic administered once a month to treat relapsing MS. This announcement follows a European Medicines Agency statement indicating that daclizumab would be urgently reviewed because 8 cases of serious inflammatory brain disorders were identified.

When the drug was approved in 2016, the FDA advised that daclizumab should only be used in patients who have failed to respond to 2 or more MS drugs because the treatment may be associated with serious safety risks, including liver damage, immune conditions and life-threatening events.

In a recent statement, Biogen and AbbVie said, “Given the nature and complexity of adverse events being reported, characterizing the evolving benefit/risk profile of Zinbryta will not be possible going forward given the limited number of patients being treated.”


Alanna McCatty

Alanna McCatty

Alanna McCatty is founder and CEO of McCatty Scholars, an organization that devises and implements financial literacy programs for students to combat the nationwide issue of the loss of educational opportunity due to the ramifications of burdensome student debt. At MedShadow, she reports on new findings and research on the side effects of prescription drugs. She is a graduate of Pace University.


Did you find this article helpful?


Latest News

FDA Recalls Metformin and NP Thyroid

FDA Recalls Metformin and NP Thyroid

The FDA has issued a recall of two drugs–NP Thyroid and Metformin–after testing revealed that they weren’t up to code. Read more below, and if you’re taking either medication, please be sure to contact your doctor for how to continue treatment responsibly.  NP Thyroid Recalled Thirteen lots of NP Thyroid,…

Can Convalescent Plasma Treat COVID-19 Patients?

Can Convalescent Plasma Treat COVID-19 Patients?

One of the most promising treatments for COVID-19 is convalescent plasma, a component of blood. People who have been infected with the virus and are now healthy have developed COVID-19-fighting antibodies, which, the theory is, can be given to people currently sick with COVID-19 so that those antibodies can boost…

  • Advertisement